{"disease":{"id":"lysosomal-alpha-1-4-glucosidase-deficiency-infantile-onset","name":"Lysosomal alpha-1,4-glucosidase deficiency - infantile onset","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"myozyme","indication_name":"Lysosomal alpha-1,4-glucosidase deficiency - infantile onset","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Myozyme","company_name":"Genzyme, a Sanofi Company","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":"1100","mechanism":null},{"drug_id":"alglucosidase-alfa","indication_name":"Lysosomal alpha-1,4-glucosidase deficiency - infantile onset","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rhgaa","generic_name":"ALGLUCOSIDASE ALFA","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC]","quality_score":66,"revenue":"1100","mechanism":"Rhgaa works by replacing the deficient enzyme in patients with Pompe disease."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}